

<b>Product Name</b>	: GZD 824
<b>Synonyms</b>	: GZD824; GZD 824; GZD-824
<b>Cat No.</b>	: M17912
<b>CAS Number</b>	: 1257628-77-5
<b>Molecular Formula</b>	: C <sub>29</sub> H <sub>27</sub> F <sub>3</sub> N <sub>6</sub> O
<b>Formula Weight</b>	: 532.57
<b>Chemical Name</b>	: 3-((1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide
<b>Description</b>	<p>GZD824 is a novel orally bioavailable inhibitor against a broad spectrum of Bcr-Abl mutants including T315I. GZD824 tightly bound to Bcr-Abl(WT) and Bcr-Abl(T315I) with K<sub>d</sub> values of 0.32 and 0.71 nM, respectively, and strongly inhibited the kinase functions with nanomolar IC<sub>50</sub> values. GZD824 potently suppressed proliferation of Bcr-Abl-positive K562 and Ku812 human CML cells with IC<sub>50</sub> values of 0.2 and 0.13 nM, respectively. GZD824 also displayed good oral bioavailability (48.7%), a reasonable half-life (10.6 h), and promising in vivo antitumor efficacy. It induced tumor regression in mouse xenograft tumor models driven by Bcr-Abl(WT) or the mutants and significantly improved the survival of mice bearing an allograft leukemia model with Ba/F3 cells harboring Bcr-Abl(T315I). GZD824 represents a promising lead candidate for development of Bcr-Abl inhibitors to overcome acquired imatinib resistance.</p>
<b>Pathway</b>	: Endocrinology/Hormones
<b>Target</b>	: AChR
<b>Receptor</b>	: Abl (E254K)
<b>Solubility</b>	: DMSO : ≥ 100 mg/mL; 187.77 mM
<b>SMILES</b>	: CN1CCN(Cc2c(cc(NC(=O)c3cc(C#Cc4cc5c([nH]nc5)nc4)c(C)cc3)cc2)C(F)(F)F)CC1
<b>Storage</b>	: (-20°C)
<b>Stability</b>	: ≥ 2 years
<b>Reference</b>	:

1. Ren X, et al. J Med Chem. 2013, 56(3), 879-894.